Thrombelastogram in Patients Receiving Antiplatelet Medication Undergoing Cardiac Surgery
Recruitment status was Recruiting
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||Thrombelastogram and Predicting Microvascular Bleeding in Patients Receiving Antiplatelet Medication Undergoing Cardiac Surgery|
- Re-sternotomy d/t Bleeding [ Time Frame: Hospitalization Period ] [ Designated as safety issue: Yes ]
- Chest tube output during first 24 hours after the surgery [ Time Frame: 24 hours ] [ Designated as safety issue: No ]
|Study Start Date:||May 2008|
|Estimated Study Completion Date:||December 2008|
|Estimated Primary Completion Date:||October 2008 (Final data collection date for primary outcome measure)|
Patients with the history of ingestion of aspirin and/or ADP receptor antagonist (clopidogrel or ticlopidine) for at least 7 days prior the surgery. All patients undergoing cardiac surgery with the use of cardiopulmonary bypass on elective and urgent basis.
Prospective observational study with blinded assessment of study endpoint variables. Collection of information concerning study endpoints will be performed by the investigator blinded to the results of preoperative testing of platelet function. The information will be collected from 60 patients undergoing cardiac surgery in the Department of Cardiac Surgery of Sheba Medical Center.
- Primary endpoint- resternotomy for bleeding after the surgery.
- Secondary endpoints- chest tube output during first 24 hours after the surgery; consumption of blood products during first 3 postoperative days.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00778492
|Sheba Medical Center||Recruiting|
|Tel Hashomer, Israel, 52621|
|Contact: Sergey Preisman, MD 052-6667205 firstname.lastname@example.org|
|Principal Investigator: Sergey Preisman, MD|
|Principal Investigator:||Sergey Preisman, MD||Sheba Medical Center|
|Study Director:||Alexander Kogan, MD||Sheba Medical Center|